A subset of patients with COPD who continue to experience exacerbations despite being on standard-of-care therapy and chronic antibiotic/PDE-4 inhibitor therapy can benefit from the blockade of the cytokines (IL-4, IL-5, IL-13) involved in type 2 inflammation. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.